• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

High dose aflibercept reduced treatment burden in patients with diabetic macular edema

byNeel MistryandTeddy Guo
April 23, 2024
in Chronic Disease, Endocrinology, Ophthalmology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks.

2. Ocular adverse events were comparable across all intervention groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Diabetic macular oedema (DMO) leads to vision loss in 5% of patients with diabetes. Anti-vascular endothelial growth factor (anti-VEGF) medications, such as aflibercept, help to resolve fluid accumulation in the macula and may improve visual acuity. However, there is little consensus around the optimal dose of aflibercept. This randomized controlled trial aimed to evaluate the safety and efficacy of high dose aflibercept (8 mg) versus standard dose (2 mg) in patients with DMO. The primary outcome of this study was a change in best-corrected visual acuity (BCVA) at week 48, while a key secondary outcome was the proportion of patients experiencing ocular adverse events. According to study results, high-dose aflibercept demonstrated non-inferiority in BCVA gains compared to standard dose. Although this study was well done, it was limited by the relatively short duration of follow-up.

Click to read the study in The Lancet

Relevant Reading: Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema

RELATED REPORTS

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

In-depth [randomized-controlled trial]: Between Jun 29, 2020, and Jun 28, 2021, 970 patients were screened for eligibility across 138 hospitals and retina clinics in 7 countries. Included were patients ≥ 18 years old with type 1 or type 2 diabetes and a known diagnosis of DMO. Eligible patients were randomly assigned to receive aflibercept 8 mg every 12 weeks (8q12), aflibercept 8 mg every 16 weeks (8q16), or aflibercept 2 mg every 8 weeks (2q8). Altogether, 658 patients (328 in 8q12, 163 in 8q16, and 167 in 2q8) were included in the final analysis. The primary outcome of change in BCVA from baseline to week 48 was non-inferior in aflibercept 8q12 and 8q16 versus aflibercept 2q8 (BCVA mean change 8.8 letters in 8q12, 7.9 letters in 8q16, and 9.2 letters in 2q8; difference in least squares mean was -0.57 letters, p<0.001 between aflibercept 8q12 and 2q8 and -1.44 letters, p=0.003 between aflibercept 8q16 and 2q8). The secondary outcome of ocular adverse events was similar across groups (32% in 8q12, 29% in 8q16, and 28% in 2q8). Findings from this study suggest that aflibercept 8 mg with extended dosing intervals could decrease treatment burden in patients with DMO.

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: afliberceptblindnessdiabetesdiabetes mellitusdiabetic macular edemaOphthalmologyType 1 Diabetes MellitusType 2 Diabetes Mellitusvisionvisual acuity
Previous Post

Minimally invasive surgery provides functional benefit in acute supratentorial intracerebral hemorrhage

Next Post

Lipid metabolic reprogramming mediated by circulating Nrg4 alleviates metabolic dysfunction-associated steatotic liver disease

RelatedReports

Chronic Disease

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

July 7, 2025
#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes
StudyGraphics

#VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes

July 7, 2025
Pediatric DKA associated with recent acute care visits
Chronic Disease

Artificial intelligence based clinical decision systems are safe and effective for diabetes management

July 3, 2025
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males
Chronic Disease

Sodium-glucose cotransporter 2 inhibitors may decrease risk of serious liver events in patients with cirrhosis

July 2, 2025
Next Post
Low free sugar diet reduces hepatic steatosis in nonalcoholic fatty liver disease in adolescent males

Lipid metabolic reprogramming mediated by circulating Nrg4 alleviates metabolic dysfunction-associated steatotic liver disease

#VisualAbstract: Sentinel-node biopsy only is noninferior to completion of axillary lymph node dissection in breast cancer with sentinel-node metastases

#VisualAbstract: Sentinel-node biopsy only is noninferior to completion of axillary lymph node dissection in breast cancer with sentinel-node metastases

Appropriate use criteria for angiography may frequently miss obstructive coronary artery disease

Beta-blockers do not lower mortality after myocardial infarction with preserved ejection fraction

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured exercise intervention improves survival in colon cancer patients
  • #VisualAbstract: Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
  • Cerebral embolic protection does not decrease stroke incidence in TAVI patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.